variants identified (Weese-Mayer et al., 2017) . Both PARMs and NPARMs impair PHOX2B function, leading to a disruption in the development of the neuronal circuits responsible for CO 2 sensitivity (Ramanantsoa & Gallego, 2013) .
CCHS varies in severity, ranging from mild hypoventilation during sleep to marked hypoxemia and hypercarbia during wakefulness and sleep associated with central apneas due to impaired respiratory center responses (Ramanantsoa & Gallego, 2013) . CCHS can occur in isolation or in association with Hirschsprung disease and/or neural crest tumors (Croaker, Shi, Simpson, Cartmill, & Cass, 1998; Ramanantsoa & Gallego, 2013) . Compared to patients with PARMs, patients with NPARMs have been shown to have an increased incidence of both Hirschsprung disease (87-100% in patients with NPARMs versus 13-20% in patients with PARMs) (Weese-Mayer et al., 2010) and neuroblastoma (50% versus 1%) (Lombardo, Kramer, Cnota, Sawnani, & Hopkin, 2017) .
Currently, there is a well-known genotype-phenotype correlation for PARMs in which patients with a higher number of polyalanine repeats have a more severe CCHS phenotype and clinical course (Weese-Mayer et al., 2010) . However, the genotype-phenotype correlation for NPARMs is not as well described. While there is evidence that NPARMs are associated with a more severe CCHS phenotype, several studies have identified novel NPARMs in CCHS patients who have a milder clinical presentation and delayed diagnosis, suggesting that NPARM-associated phenotypes may depend on the type and location of the mutation (Cain et al., 2017; Lombardo et al., 2017; Magalhaes et al., 2015; Parodi et al., 2008; Trochet et al., 2009) . In this clinical report, we present two patients with NPARMs who have distinct differences in phenotype severity with mild and atypical presenta- Moreover, it is important to note that a clinically milder degree of hypercarbia does not necessarily rule out CCHS and there needs to be a very high index of suspicion to evaluate the patient accordingly. (Table 1) . She has no evidence of developmental delays or pulmonary hypertension.
| R E SU LTS

| Patient 2
Patient 2 is a 2-month-old female born at 39 1/7 weeks by repeat cesarean section to a 31-year-old mother with severe obesity and type II diabetes mellitus, for which she has been taking glyburide. At birth, she presented with hypoglycemia, hypercarbia, stridor, and gastroesophageal reflux disease, and a swallow study demonstrated aspiration of thin liquids. Despite caffeine, lasix, and oxygen administration, she continued to demonstrate episodic desaturations with stridor and congestion. Due to her oxygen requirement and ongoing desaturations, a sleep study was performed demonstrating severe obstructive apnea and frequent moderate desaturations (nadir SaO 2 81%) ( Table 1) (Lombardo et al., 2017) and is expected to result in loss of PHOX2B function via premature protein truncation or nonsense-mediated mRNA decay.
Due to severe daytime and nighttime hypercarbia and shallow respiratory efforts, she underwent tracheostomy and placement of a gastrostomy tube. She was initially on 24-hr ventilator support, with which her CO 2 levels were less than 40 torr, and is currently on heat and moisture exchanger 2 hr during the day with spot check ETCO 2 and remains fully vented at night. She has no cardiac rhythm disturbances. Of note, a liver mass was incidentally found on abdominal ultrasound screening for adrenal masses and followup contrast-enhanced ultrasound showed that the mass is likely a hemangioma. Note. Electroencephalogram (EEG) arousal index: Number of arousal divided by total sleep duration; Respiratory arousal index (RAI): Total number of arousal due to respiratory events divided by total sleep duration; Apnea hypopnea index (AHI): Total number of apnea and hypopneas divided by total sleep duration. Based on obstructive or central events respective AHI is calculated (Berry et al., 2017) .
| D ISC USSION
patients have been diagnosed with this disease to date. Of note, the nearby p.R100L mutation has been identified in familial neuroblastoma as well as a patient with CCHS, sporadic neuroblastoma, and Hirschprung disease, and the p.R141Q mutation has been identified in a patient with CCHS, Hirschprung disease, and neuroblastoma (Raabe et al., 2008; Trochet et al., 2004; Trochet, O'Brien, et al., 2005b) ; thus, missense mutations in this region may lead to non-isolated CCHS.
Patient 1 also developed severe OSA due to adenotonsillar hypertrophy, and the severity of OSA was likely worsened due to her underlying CCHS, which may have also contributed to her post-operative complications after adenotonsillectomy. She never had a tracheostomy or gastrostomy tube and has been managed with nocturnal BIPAP. To date she is doing well developmentally, and she will continue to require close follow up in case respiratory support is needed during future respiratory illnesses. Evidence from Patient 1 and others suggest that CCHS is not always associated with a severe respiratory phenotype, and in fact can be later diagnosed in patients who are asymptomatic at birth (Cain et al., 2017; Lombardo et al., 2017; Magalhaes et al., 2015; Parodi et al., 2008; Trochet et al., 2009; Weese-Mayer et al., 2010) . For example, the majority of NPARMs reported to date are frameshift variants. Frameshifts in exon 3, which can affect the polyalanine repeat region, are associated with a severe phenotype, but frameshift variants in the end of exon 2 or the beginning of exon 3 are associated with a milder phenotype (Cain et al., 2017; Low et al., 2014; Trochet, Hong, et al., 2005a) .
In contrast to Patient 1, Patient 2 presented at birth with a more severe clinical course characterized by persistent severe desaturations, severe hypercarbia while awake and asleep, OSA, and oropharyngeal airway collapse requiring tracheostomy and placement of a gastrostomy tube. PHOX2B genetic testing revealed a normal number of polyalanine repeats and identified a pathogenic nonsense NPARM recently reported in a different family (Lombardo et al., 2017) . In that family, the mutation was maternally inherited in two siblings and was associated with a variable phenotype. In terms of respiratory issues, one child was noted to have desaturation episodes, one child was diagnosed with central apnea, and the mother reported possible apneic episodes during sleep. In addition, both children were diagnosed with Hirschsprung's disease, and both children and the mother have mildly dysmorphic facial features and anisocoria. Interestingly, there is also a history of congenital heart disease, with one child having aberrant origin of the left coronary artery and the mother having a complete vascular ring and right-sided aortic arch. To date, both children have screened negative for neural crest tumors (Lombardo et al., 2017) . In comparison, our Patient 2 has a severe phenotype with significant respiratory compromise and an incidental liver hemangioma, but no evidence of Hirschprung's or congenital heart disease. For the nonsense NPARMs reported to date, the location of the mutation appears to be associated with the phenotypic severity. Although a severe clinical presentation was reported in a patient with p.K155*, milder clinical presentations are reported for patients carrying nonsense mutations upstream of p.
M18/M21, likely due to translational reinitiation at p.M18 or p.M21 (Cain et al., 2017; Lombardo et al., 2017; Magalhaes et al., 2015; Parodi et al., 2008; Trochet et al., 2009 ). In the future, additional research is needed on patients with NPARMs to further understand and characterize the variety of associated clinical presentations and disease progression.
In summary, the key learning points from this report are that (a) genetic testing of PHOX2B needs to be done to investigate for NPARMs in addition to PARMs if there is suspicion for CCHS and (b)
CCHS patients with NPARMs can present with a diverse range of clinical phenotypes. Thus, it is possible that additional factors besides PHOX2B mutations, such as epigenetic alterations, may contribute to the clinical presentation of these patients.
